| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:135.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Cardiology and Uppsala Clinical Research Centre, Uppsala, Sweden (L.W., B.L.); Samu de Lille, Lille, France (P.G.); Department of Cardiology, University of Alberta, Edmonton, Canada (P.W.A.); Division of Cardiology, Duke University Medical Center, Durham, NC (C.B.G.); Department of Cardiology, Royal Victoria Hospital, Belfast, Northern Ireland (A.A.J.A.); Department of Cardiopulmology, Benjamin Franklin Medical Center, Free University of Berlin, Germany (H.R.A.); Biostatistical Centre, University of Leuven, Belgium (K.B.); Boehringer-Ingelheim, Ingelheim am Rhein, Germany (T.D.); Department of Medicine, University Central Hospital, Helsinki, Finland (M.M.); University Medical Center, Nijmegen, the Netherlands (F.V.); and Department of Cardiology, University of Leuven, Leuven, Belgium (F.V.d.W.).
Correspondence to Lars Wallentin, MD, PhD, Professor of Cardiology, Head Uppsala Clinical Research Center, Uppsala Clinical Research Center, Uppsala University Hospital, SE 751 85 Uppsala, Sweden. E-mail Lars.Wallentin{at}ucr.uu.se
Background The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may facilitate prehospital reperfusion and further improve clinical outcome in patients with ST-elevation myocardial infarction.
Methods and Results In the prehospital setting, 1639 patients with ST-elevation myocardial infarction were randomly assigned to treatment with tenecteplase and either (1) intravenous bolus of 30 mg enoxaparin (ENOX) followed by 1 mg/kg subcutaneously BID for a maximum of 7 days or (2) weight-adjusted unfractionated heparin (UFH) for 48 hours. The median treatment delay was 115 minutes after symptom onset (53% within 2 hours). ENOX tended to reduce the composite of 30-day mortality or in-hospital reinfarction, or in-hospital refractory ischemia to 14.2% versus 17.4% for UFH (P=0.080), although there was no difference for this composite end point plus in-hospital intracranial hemorrhage or major bleeding (18.3% versus 20.3%, P=0.30). Correspondingly, there were reductions in in-hospital reinfarction (3.5% versus 5.8%, P=0.028) and refractory ischemia (4.4% versus 6.5%, P=0.067) but increases in total stroke (2.9% versus 1.3%, P=0.026) and intracranial hemorrhage (2.20% versus 0.97%, P=0.047). The increase in intracranial hemorrhage was seen in patients >75 years of age.
Conclusions Prehospital fibrinolysis allows 53% of patients to receive reperfusion treatment within 2 hours after symptom onset. The combination of tenecteplase with ENOX reduces early ischemic events, but lower doses of ENOX need to be tested in elderly patients. At present, therefore, tenecteplase and UFH are recommended as the routine pharmacological reperfusion treatment in the prehospital setting.
Key Words: myocardial infarction fibrinolysis hemorrhage heparin reperfusion
This article has been cited by other articles:
![]() |
D. J. Quinlan and J. W. Eikelboom Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction Arch Intern Med, June 22, 2009; 169(12): 1163 - 1164. [Full Text] [PDF] |
||||
![]() |
E. A Nutescu, S. A Spinler, A. Wittkowsky, and W. E Dager Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings Ann. Pharmacother., June 1, 2009; 43(6): 1064 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
N A Rajabali, R T Tsuyuki, S Sookram, S H Simpson, and R C Welsh Evaluation of attitudes and perceptions of key clinical stakeholders regarding out-of-hospital diagnosis and treatment of ST elevation myocardial infarction patients using a region-wide survey Emerg. Med. J., May 1, 2009; 26(5): 371 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Bongard, J Puel, D Savary, L Belle, S Charpentier, Y Cottin, L Soulat, M Elbaz, D Miljkovic, P. G Steg, et al. Predictors of infarct artery patency after prehospital thrombolysis: the multicentre, prospective, observational OPTIMAL study Heart, May 1, 2009; 95(10): 799 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Horne, C Weston, T Quinn, A Hicks, L Walker, R Chen, and J Birkhead The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP) Heart, April 1, 2009; 95(7): 559 - 563. [Abstract] [Full Text] [PDF] |
||||
![]() |
R D Lopes, K S Pieper, J R Horton, S M Al-Khatib, L K Newby, R H Mehta, F Van de Werf, P W Armstrong, K W Mahaffey, R A Harrington, et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation Heart, July 1, 2008; 94(7): 867 - 873. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF] |
||||
![]() |
American College of Cardiology/American Heart Asso, Developed in Collaboration With the Canadian Cardi, Endorsed by the American Academy of Family Physici, 2007 Writing Group to Review New Evidence and Upda, E. M. Antman, M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction J. Am. Coll. Cardiol., January 15, 2008; 51(2): 210 - 247. [Full Text] [PDF] |
||||
![]() |
E. M. Antman, M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, J. S. Hochman, H. M. Krumholz, G. A. Lamas, C. J. Mullany, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee Circulation, January 15, 2008; 117(2): 296 - 329. [Full Text] [PDF] |
||||
![]() |
I. George and M. C. Oz Myocardial Revascularization after Acute Myocardial Infarction Card. Surg. Adult, January 1, 2008; 3(2008): 669 - 696. [Full Text] |
||||
![]() |
C. Brasselet, S. Tassan, P. Nazeyrollas, M. Hamon, and D. Metz Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: results of the FARMI Trial Heart, December 1, 2007; 93(12): 1556 - 1561. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Boden, K. Eagle, and C. B. Granger Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A.A. Fox, J.-P. Bassand, S. R. Mehta, L. Wallentin, P. Theroux, L. S. Piegas, V. Valentin, T. Moccetti, S. Chrolavicius, R. Afzal, et al. Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non ST-Segment Elevation Acute Coronary Syndromes Ann Intern Med, September 4, 2007; 147(5): 304 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Murphy, C. M. Gibson, D. A. Morrow, F. Van de Werf, I. B. Menown, S. G. Goodman, K. W. Mahaffey, M. Cohen, C. H. McCabe, E. M. Antman, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis Eur. Heart J., September 1, 2007; 28(17): 2077 - 2086. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Alexander, L. K. Newby, P. W. Armstrong, C. P. Cannon, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al. Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology Circulation, May 15, 2007; 115(19): 2570 - 2589. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. White, E. Braunwald, S. A. Murphy, A. J. Jacob, N. Gotcheva, L. Polonetsky, and E. M. Antman Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25 Eur. Heart J., May 1, 2007; 28(9): 1066 - 1071. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF] |
||||
![]() |
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF] |
||||
![]() |
P. W. Armstrong and WEST Steering Committee A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study Eur. Heart J., July 1, 2006; 27(13): 1530 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W.A. Verheugt Reperfusion Therapy Starts in the Ambulance Circulation, May 23, 2006; 113(20): 2377 - 2379. [Full Text] [PDF] |
||||
![]() |
P. W. Armstrong, W.-C. Chang, L. Wallentin, P. Goldstein, C. B. Granger, K. Bogaerts, T. Danays, F. Van de Werf, and for the ASSENT-3 and ASSENT-3 PLUS Investigators Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. Can. Med. Assoc. J., May 9, 2006; 174(10): 1421 - 1426. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Bailey and S. R. Steinhubl Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data. Can. Med. Assoc. J., May 9, 2006; 174(10): 1431 - 1432. [Full Text] [PDF] |
||||
![]() |
E. M. Antman, D. A. Morrow, C. H. McCabe, S. A. Murphy, M. Ruda, Z. Sadowski, A. Budaj, J. L. Lopez-Sendon, S. Guneri, F. Jiang, et al. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction N. Engl. J. Med., April 6, 2006; 354(14): 1477 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Gibbons and V. Fuster Therapy for Patients with Acute Coronary Syndromes -- New Opportunities N. Engl. J. Med., April 6, 2006; 354(14): 1524 - 1527. [Full Text] [PDF] |
||||
![]() |
W.-C. Chang, P. Kaul, Y. Fu, C. M. Westerhout, C. B. Granger, K. W. Mahaffey, L. Wallentin, F. Van de Werf, P. W. Armstrong, and for the ASSENT-3 Investigators Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction Eur. Heart J., February 2, 2006; 27(4): 419 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Meurin, J. Y. Tabet, H. Weber, N. Renaud, and A. B. Driss Low-Molecular-Weight Heparin as a Bridging Anticoagulant Early After Mechanical Heart Valve Replacement Circulation, January 31, 2006; 113(4): 564 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Bueno, M. Martinez-Selles, E. Perez-David, and R. Lopez-Palop Mechanisms of death in elderly patients with acute myocardial infarction exposed to fibrinolytic therapy: reply Eur. Heart J., January 2, 2006; 27(2): 246 - 247. [Full Text] [PDF] |
||||
![]() |
M. S. Sabatine, D. A. Morrow, G. Montalescot, M. Dellborg, J. L. Leiva-Pons, M. Keltai, S. A. Murphy, C. H. McCabe, C. M. Gibson, C. P. Cannon, et al. Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial Circulation, December 20, 2005; 112(25): 3846 - 3854. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials Circulation, December 20, 2005; 112(25): 3855 - 3867. [Abstract] [Full Text] [PDF] |
||||
![]() |
Part 8: Stabilization of the Patient With Acute Coronary Syndromes Circulation, December 13, 2005; 112(24_suppl): IV-89 - IV-110. [Full Text] [PDF] |
||||
![]() |
R C Welsh and P W Armstrong It's a matter of time: contemporary pre-hospital management of acute ST elevation myocardial infarction Heart, December 1, 2005; 91(12): 1524 - 1526. [Full Text] [PDF] |
||||
![]() |
Part 5: Acute Coronary Syndromes Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72. [Full Text] [PDF] |
||||
![]() |
R C Welsh, W Chang, P Goldstein, J Adgey, C B Granger, F W A Verheugt, L Wallentin, F Van de Werf, P W Armstrong, and on behalf of the ASSENT-3 PLUS Investigators Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial Heart, November 1, 2005; 91(11): 1400 - 1406. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Armstrong Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction Eur. Heart J., October 1, 2005; 26(19): 1937 - 1938. [Full Text] [PDF] |
||||
![]() |
C. J. Terkelsen, J. F. Lassen, B. L. Norgaard, J. C. Gerdes, S. H. Poulsen, K. Bendix, J. P. Ankersen, L. B.-H. Gotzsche, F. K. Romer, T. T. Nielsen, et al. Reduction of treatment delay in patients with ST-elevation myocardial infarction: impact of pre-hospital diagnosis and direct referral to primary percutanous coronary intervention Eur. Heart J., April 2, 2005; 26(8): 770 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S Kalus and L. R Moser Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction Ann. Pharmacother., March 1, 2005; 39(3): 481 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Mehta, C. B. Granger, K. P. Alexander, E. Bossone, H. D. White, and M. H. Sketch Jr Reperfusion strategies for acute myocardial infarction in the elderly: Benefits and risks J. Am. Coll. Cardiol., February 15, 2005; 45(4): 471 - 478. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Machecourt, E. Bonnefoy, G. Vanzetto, P. Motreff, S. Marliere, A. Leizorovicz, B. Allenet, J. M. Lacroute, J. Cassagnes, and P. Touboul Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: The Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study J. Am. Coll. Cardiol., February 15, 2005; 45(4): 515 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
The CREATE Trial Group Investigators* Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation JAMA, January 26, 2005; 293(4): 427 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Wiggins and S. Spinler Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes Journal of Pharmacy Practice, October 1, 2004; 17(5): 347 - 369. [Abstract] [PDF] |
||||
![]() |
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 549S - 575S. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Antman and F. Van de Werf Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction Circulation, June 1, 2004; 109(21): 2480 - 2486. [Full Text] [PDF] |
||||
![]() |
M. Kroese, D. Kanka, P. Weissberg, B. Arch, and J. Scott Prehospital thrombolysis--calculated health benefit for catchment population of one hospital J R Soc Med, May 1, 2004; 97(5): 230 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Armstrong and R. C. Welsh Tailoring therapy to best suit ST-segment elevation myocardial infarction: searching for the right fit Can. Med. Assoc. J., October 28, 2003; 169(9): 925 - 927. [Full Text] |
||||
![]() |
F. W.A. Verheugt Combining glycoprotein blockers with fibrinolysis: a bold stroke? Eur. Heart J., October 2, 2003; 24(20): 1801 - 1803. [Full Text] [PDF] |
||||
![]() |
Prehospital Thrombolysis with LMWH vs. UFH Journal Watch Cardiology, September 19, 2003; 2003(919): 3 - 3. [Full Text] |
||||
![]() |
Prehospital TNK Plus Enoxaparin Increases Risk for Intracranial Hemorrhage Journal Watch Emergency Medicine, September 10, 2003; 2003(910): 2 - 2. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |